1
0
0
(1 - 14 von 15
)
Controlled Release Society
www.controlledreleasesociety.org
Patrick Baumhof, Regina Heidenreich, Birgit Scheel, Söhnke Voss, Karl-Josef Kallen, Mariola Fotin-Mleczek. Institutions. CureVac GmbH, Tübingen,
Messenger RNA vaccination and B-cell responses in NSCLC ...American Society of Clinical Oncology (ASCO)
meetings.asco.org
... Birgit Scheel, Sven D. Koch, Thomas Lander, Gerd Rippin, Volker Wiegand, Ulrike Senta Gnad-Vogt, Karl-Josef Kallen, Alexander Knuth. Organizations Birgit Scheel, Sven D. Koch, Thomas Lander, Gerd Rippin, Volker Wiegand, Ulrike Senta Gnad-Vogt, Karl-Josef Kallen, Alexander Knuth. Organizations.
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
... Andreas Groeschel, Birgit Scheel, Sven D. Koch, Thomas Lander, Gerd Rippin, Volker Wiegand, Ulrike Senta Gnad-Vogt, Karl-Josef Kallen, Alexander Knuth ...
Vaccines & VaccinationWalsh Medical Media
www.walshmedicalmedia.com
Regina Heidenreich, Benjamin Petsch, Mariola Fotin-Mleczek, Patrick Baumhof, Birgit Scheel, Söhnke Voss, Edith Jasny, Thomas Kramps and Karl-Josef Kallen.
Phase Ib study evaluating a self-adjuvanted mRNA cancer ...Goethe-Universität Frankfurt
publikationen.ub.uni-frankfurt.de
von M Sebastian · · Zitiert von: 124 — Koch, Birgit Scheel, Mariola Fotin-Mleczek, Regina Heidenreich, Karl-Josef Kallen, Ulrike Gnad-Vogt, Alfred Zippelius. Background: Advanced non-small cell ... von M Sebastian · · Zitiert von: 124 — Koch, Birgit Scheel, Mariola Fotin-Mleczek, Regina Heidenreich, Karl-Josef Kallen, Ulrike Gnad-Vogt, Alfred Zippelius. Background: Advanced non-small cell ...
A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared...
jitc.biomedcentral.com
Affiliations. CureVac GmbH, Tuebingen, Germany. Karl-Josef Kallen, Ulrike Gnad-Vogt & Birgit Scheel. Rippin Consulting, Solingen, Germany.
OPUS 4 | Phase Ib evaluation of a self-adjuvanted protamine...
publikationen.ub.uni-frankfurt.de
... Frank Griesinger, Karl-Josef Kallen, Mariola Fotin-Mleczek, Andreas Schröder, Birgit Scheel, Anke Muth, Tobias Seibel, Claudia Stosnach, ...
RNAdjuvant®, a novel, highly-potent RNA-based adjuvant ...jitc.biomedcentral.com › articles
jitc.biomedcentral.com
AP · ... Birgit Scheel, Söhnke Voss, Karl-Josef Kallen & Mariola Fotin-Mleczek. CureVac GmbH, Tübingen, Germany. Johannes Lutz. CureVac GmbH Frankfurt ...
A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared...
link.springer.com
Karl-Josef Kallen; Ulrike Gnad-Vogt; Birgit Scheel; Gerd Rippin; Arnulf Stenzl. Karl-Josef Kallen. 1. Ulrike Gnad-Vogt. 1. Birgit Scheel. 1.
ASCO Publications
ascopubs.org
von M Sebastian · · Zitiert von: 18 — ... Birgit Scheel, Sven D. Koch, Thomas Lander, Gerd Rippin, Volker Wiegand, Ulrike Senta Gnad-Vogt, Karl-Josef Kallen, and Alexander Knuth Show ...
Additional file 5: of Phase Ib evaluation of a self-adjuvanted ...springernature.figshare.com › articles › Additional_file_5_of_Phase_Ib_...
springernature.figshare.com
... Frank Griesinger Karl-Josef Kallen Mariola Fotin-Mleczek Andreas Schröder Birgit Scheel Anke Muth Tobias Seibel Claudia Stosnach Fatma ...
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccineresearch.kssg.ch › Publikationen › L-en
research.kssg.ch
... Gerd Rippin, Sven D Koch, Birgit Scheel, Mariola Fotin-Mleczek, Regina Heidenreich, Karl-Josef Kallen, Ulrike Gnad-Vogt & Alfred Zippelius ...
Additional file 1: of Phase Ib evaluation of a self-adjuvanted...
figshare.com
· ... JĂźrgen Alt, Helge Bischoff, Michael GeiĂŸler, Frank Griesinger, Karl-Josef Kallen, Mariola Fotin-Mleczek, Andreas SchrĂśder, Birgit Scheel, ...
RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines...
www.jimmunol.org
· ... Aleksandra Kowalczyk, Patrick Baumhof, Birgit Scheel, Söhnke Voss, Karl-Josef Kallen, Mariola Fotin-Mleczek and Ulrike Gnad-Vogt.
Alle Infos zum Namen "Birgit Scheel"
sortiert nach Relevanz / Datum